INM   $0.6804  -2.06% Market Closed After Close 0.668 -1.82%

InMed Pharmaceuticals Inc.
Last Events:

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it crossed the signal line from the top and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: signal line crossed the middle level.

2023-08-03 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: up-crossing the middle level.

2023-08-03 Signal in RSI changed from bullish recovery to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-03 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-03 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 0.00
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.83
Target: 20.00
High with 49% probability: 3.39
Analyst Recommendations:
Number of estimates 1
Target Price Mean 20.00
Mean unverified/preliminary 20.00 / 20.00
Target Price Low / High 20.00 / 20.00
Median / STD DEV 20.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Sell Sell
rsi Sell ActivelyBuy Sell
macd Sell None None
stoch None None None
ma20 None Sell Sell
ma50 None None None
ma100 Buy Sell None
Candlestick PatternMarch 27, 2026 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CA4576377002
ceo Mr. Eric A. Adams B.S. Chem., M.I.B.
Website https://www.inmedpharma.com
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.